abstract Expression levels of BDNF and trkB, primary components of an important neurotrophin signaling pathway, have been reported to be abnormal in neurodegenerative dementias. Here, we used a novel postmortem brain tissue stimulation paradigm to examine BDNF-induced trkB signaling in participants of the Religious Orders Study, a large longitudinal clinicopathological study of aging and cognition. Thawed slices of anterior cingulate cortex were incubated in BDNF and changes in phosphorylated trkB and downstream signaling molecules ERK2 and Akt were measured, as well as the association of NMDA receptors with trkB. We found that stimulation with BDNF induced much greater activity of the BDNF-trkB signaling pathway in brain tissues of people with cognitive decline and AD, as evidenced by significantly more phosphorylation of trkB (pY-trkB), ERK2 (pY/pT-ERK2), Akt (pS-Akt), and greater BDNF-induced coupling of trKB with NMDAR2A/B. These findings were independent of PHFtau neurofibrillary tangle and amyloid-b plaque densities and other potentially confounding variables. Regression analyses with clinical features further characterized significant relationships between measures of BDNF-trkB activation and domains of cognition and emotional functioning. Increased BDNF-trkB signaling with cognitive decline could reflect a primary derangement of pathway functioning or a compensatory neuroplastic response to counteract neural injury associated with neurodegenerative processes.
introduction
Dementia is a frequent and dread occurrence in late life, characterized by progressive loss of memory and other cognitive and functional abilities. Alzheimer's disease (AD), cerebrovascular disease, Lewy body diseases, and frontotemporal dementias are the most common causes of dementia in the elderly. BDNF is an essential neurotrophic factor that is expressed in neurons and glia throughout the brain. Acting through its principal receptor, trkB [5] [6] [7] [8] , BDNF regulates activity-dependent synaptic plasticity and thus, BDNF-trkB signaling is a pivotal modulator of memory processing and storage (for review see [9] ).
BDNF-trkB signaling is also critically involved in the genesis, differentiation, maintenance, and survival of many major neuronal types and synapses in the central and peripheral nervous systems [10, 11] .
Abnormalities in BDNF-trkB expression and signaling have been reported in AD and other neurodegenerative dementias, ischemic brain injury, oxidative damage, as well as in depression and other neuropsychiatric illnesses [12] [13] [14] . However, the nature, causes and/or consequences of these abnormalities are complex or ill defined. For instance, BDNF mRNA and protein expression have been reported to be both decreased and increased in brain tissue from people with AD [7, 10, [15] [16] [17] and in amyloid-b-producing transgenic mice [18, 19] . Genetic studies have reported that Val66Met BDNF polymorphisms may be associated with progression of cognitive decline [20] and brain metabolism in AD [21] as well as the presence of depression in AD [22] . Serum biomarker studies have described both decreased and increased levels of BDNF in MCI and AD [23] [24] [25] , while low cerebrospinal fluid levels of BDNF have been associated with agerelated cognitive decline, even after adjusting for amyloid and tau levels, and APOE and BDNF Val66Met genotypes [26] . Deprivation of BDNF from hippocampal neuron culture media promotes production of amyloid-b [27] .
Furthermore, amyloid-b negatively impacts trkB function and this has been proposed to contribute to reduced neuronal survival in AD brains [28] . Finally, BDNF has been shown to protect against the neurotoxic effects of amyloid-bin rats [29] .
Here, we used a novel postmortem brain tissue stimulation paradigm to examine the integrity of BDNF-induced trkB signaling in older persons participating in the Religious Orders Study (see Table 1 ), a large prospective clinicopathological studies program of aging and cognition [30] . Cognition in the sample spanned a range from normal to advanced dementia. We found that BDNF-trkB signaling activity remained responsive with advancing age and became hyperactive with increasing cognitive impairment. We further unexpectedly found that this increase in trkB signaling occurred independently of neurodegenerative pathology in these brains. Finally, we observed a relationship between anxiety symptoms, BDNF-trkB signaling, and cognitive impairment raising the possibility that BDNF-trkB signaling may mediate a distress-cognition association. Depression Scale (CES-D) [35] . These were also transformed into z-scores and averaged into a combined "psychological distress" index.
experimental Procedures

Postmortem tissue
After death, subjects' brains were removed in a standard fashion as described previously [36] [37] [38] 
Ex-vivo incubation with BDNF
BDNF stimulation of postmortem tissue was conducted with methods adapted from previously described studies of other ligands [49, 50] . Postmortem anterior cingulate gray matter blocks were gradually thawed in a -20°C freezer and were sliced using a chilled McIlwain tissue chopper (100 mm x 100 mm x 3 mm).
The intact tissue slices were suspended in ice- 
results
Baseline expression levels of BDNF and trkB are unrelated to cognitive status
Total expression levels of Pro-BDNF, BDNF, fulllength trkB (145 kDa), and truncated trkB (95kDa)
were measured by Western blotting in tissue homogenates of anterior cingulate cortex (see Figure 1a and Table 2 ). There were no significant associations between levels of Pro-BDNF or BDNF and global cognition in the whole cohort, nor differences between those classified into AD (Table 2) , although it was significantly greater in AD (6.1-fold) compared to those without (4.7-fold).
Increased association of NMDA receptor NR2A/B and trkB with cognitive impairment
There is an important interaction between trkB and NMDA receptors, especially NR2B, which is enhanced upon BDNF treatment and decreased with tyrosine kinase inhibition. We have previously reported that psychological distress is associated with increased risk for dementia and more 
Discussion
In this novel set of experiments, we showed that deteriorating cognition and a clinical diagnosis Most published studies of BDNF in AD have highlighted decreases in expression levels of BDNF and trkB [12, 13, 16, 17, [62] [63] [64] [65] [66] [67] [68] Extensive data demonstrate that BDNF affects neurotransmission through both pre-and postsynaptic mechanisms to affect cognition [71, 72] .
BDNF-induced trkB activation leads to enhanced glutamatergic neurotransmission [73] , rapid NMDAR subunit phosphorylation [74] , and long-term potentiation (LTP) [75] . In spatial memory tasks with rodents, activated trkB in hippocampus is selectively and transiently increased after maze training [51] . The role of trkB activation in learning and memory is supported by data showing intracerebroventricular administration of antisense BDNF oligonucleotides to maze-trained rats dampens their previously acquired spatial memory [76] . Moreover, addition of exogenous BDNF rescues LTP defects in BDNF deficient mutant mice [77] and anti-BDNF antibodies impair memory in water maze and passive avoidance tests [78, 79] . Conditioned trkB-CRE knockout in forebrain during postnatal development severely impairs complex learning and shortterm plasticity [80] . 
